Canopy Growth produces and sells cannabis products and manufactures premium vaporizers through its Storz & Bickel subsidiary. The company operates through two segments: Cannabis and Storz & Bickel. In the Cannabis segment, Canopy Growth serves medical patients in Canada, Germany, Poland, and Australia, and adult-use consumers in Canada. Canopy Growth sells medical products like dried flower, oils, and softgels via pharmacies or company-owned e-commerce platforms. In the Canadian adult-use market, Canopy Growth sells flower, pre-rolls, edibles, and vapes to provincial wholesale authorities who distribute to retailers. Storz & Bickel manufactures dry herb and medical-grade vaporizers, including the Volcano and Mighty+, which are sold in over 100 markets. Canopy Growth cultivates and processes cannabis primarily at facilities in Ontario and Quebec. The company also maintains a non-controlling interest in Canopy USA, which holds U.S. cannabis assets like Wana and Acreage, to preserve market exposure while complying with federal law. Strategy focuses on expanding international medical sales in Germany and Poland, improving Canadian adult-use profitability by rationalizing SKUs, and launching new vaporizer models. Management is currently executing a cost-reduction program to achieve positive adjusted EBITDA and free cash flow.